Hepatitis C

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

April 17, 2020


Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

March 02, 2020


Hepatitis C virus (HCV) has contributed to more US patient deaths than the next 60 reportable infectious diseases combined. The United States Preventive Services Task Force has issued updated guidelines on screening for HCV that account for the larger proportion of this patient group that now includes persons who inject drugs, as well as the shift from interferon-based therapy to regimens composed of direct-acting antiviral (DAA) medications.

Discontinuation of New Hepatitis C Drugs Among Medicare Patients

February 12, 2020


Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

December 13, 2019


Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.

Podcast: This Week in Managed Care—Opioid Ruling and Settlement, and Other Health News

September 01, 2019


Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

What We're Reading: State-Based ACA Exchange; Surgeon General on Marijuana Use; HCV Drugs and Liver Impairment

August 30, 2019


Maine wants to take more control over its Affordable Care Act marketplace; Surgeon General Jerome Adams, MD, MPH, has issued an advisory against marijuana use in young people and pregnant people; the FDA is warning of rare occurrences of serious liver injury from use of 3 hepatitis C virus (HCV) drugs.

This Week in Managed Care: August 30, 2019

August 30, 2019


This week, the top managed care stories included a huge ruling against one opioid maker and a settlement offer from another; an expert panel calling for broader screening for hepatitis C; a review showing there are more fatal events linked to a multiple sclerosis drug than previously known.

5 Findings From the August 2019 Issue of AJMC®

August 16, 2019


The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.

Late Diagnosis of Hepatitis C Virus Infection, 2014-2016: Continuing Missed Intervention Opportunities

August 13, 2019


Late hepatitis C virus infection diagnosis points to a need for earlier screening and treatment before the onset of severe liver disease leading to high cost and diminished outcomes.